The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Osteopontin as a multifaceted driver of bone metastasis and drug resistance
Open accessAbstract
Metastasis to bone frequently occurs in majority of patients with advanced breast cancer and prostate cancer, leading to devastating skeletal-related events and substantially reducing the survival of patients. Currently, the crosstalk between tumor cells and the bone stromal compartment was widely investigated for bone metastasis and the resistance to many conventional therapeutic methods. Osteopontin (OPN), also known as SPP1 (secreted phosphoprotein 1), a secreted and chemokine-like glyco-phosphoprotein is involved in tumor progression such as cell proliferation, angiogenesis, and metastasis. The expression of OPN in tumor tissue and plasma has been clinically proved to be correlated to poor prognosis and shortened survival in patients with breast cancer and prostate cancer. This review summarizes the multifaceted roles that OPN plays in bone microenvironment and drug resistance, with emphasis on breast and prostate cancers, via binding to αvβ3 integrin and CD44 receptor and inducing signaling cascades. We further discuss the promising therapeutic strategy for OPN targeting, mainly inhibiting OPN at transcriptional or protein level or blocking it binding to receptor or its downstream signaling pathways. The comprehending of the function of OPN in bone microenvironment is crucial for the development of novel biomarker and potential therapeutic target for the diagnosis and treatment of bone metastasis and against the emergence of drug resistance in advanced cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Vergis, R., Corbishley, C. M., Norman, A. R., Bartlett, J., Jhavar, S., Borre, M., Heeboll, S., Horwich, A., Huddart, R., Khoo, V., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70076-7 · Cited by 282
Mandal, C. C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G. G., & Ghosh-Choudhury, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193714 · Cited by 138
Cited by
Magnetic Nanoparticles in Targeted Drug Delivery: a Review
kianfar, E. (2021) · Journal of Superconductivity and Novel Magnetism · doi:10.1007/s10948-021-05932-9 · Cited by 280
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
Kariya, Y., & Kariya, Y. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030033 · Cited by 14
Metadata
- Authors
- Pang, X., Gong, K., Zhang, X., Wu, S., Cui, Y., & Qian, B.-Z.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 144
- Pages
- 235-244
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2941669327
- Cited by
- 184
- References
- 4
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteopontin as a multifaceted driver of bone metastasis and drug resistance. https://app.cochat.ai/papers/10.1016/j.phrs.2019.04.030
- The paper
- Pang, X., Gong, K., Zhang, X., Wu, S., Cui, Y., & Qian, B.-Z. (2019). Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharmacological Research. https://doi.org/10.1016/j.phrs.2019.04.030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
